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Abstract
Background: An unusually high number of severe pneumonia cases with considerable mortality is being observed with the
pandemic H1N1 2009 virus infections globally. In India, all mild as well as critically ill cases were admitted and treated in the
government hospitals during the initial phase of the pandemic. The present study was undertaken during this early phase of
the pandemic.
Methodology: The role of viral load and host factors in the pathogenesis were assessed by examining 26 mild (MP), 15
critically ill patients (CIP) and 20 healthy controls from Pune, India. Sequential blood and lung aspirate samples were
collected from CIP. Viral load and cytokines/chemokine levels were determined from the plasma and lung aspirates of the
patients. TLR levels were determined by staining and FACS analysis. Gene profiling was done for both cells in the lung
aspirates and PBMCs using TaqMan Low Density arrays. Antibody titres and isotyping was done using HA protein based
ELISAs.
Principal Findings: 13/15 critically ill patients expired. All plasma samples were negative for the virus irrespective of the
patient’s category. Sequential lung samples from CIP showed lower viral loads questioning association of viral replication with
the severity. Anti-rpH1N1-09-HA-IgG titres were significantly higher in critically ill patients and both categories circulated
exclusively IgG1 isotype. Critically ill patients exhibited increase in TLR-3, 4, 7 and decrease in TLR-2 expressions. The disease
severity correlated with increased plasma levels of IL1RA, IL2, IL6, CCL3, CCL4 and IL10. Majority of the immune-function genes
were down-regulatedinthePBMCs and up-regulatedinthe cells from lung aspiratesof critically illpatients. Nodistinct pattern
differentiating fatal and surviving patients was observed when sequential samples were examined for various parameters.
Conclusions: Disease severity was associated with pronounced impairment of host immune response.
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Introduction
The first pandemic of this century was unexpectedly caused by a
novel swine-origin H1N1 virus, the pandemic H1N1 (2009) virus
(p-H1N1-09). Mexico was the first country to be affected in early
March with reports of mild respiratory infection as well as severe
pneumonia cases and considerable mortality [1,2]. Several
countries were subsequently affected reporting variable mortality,
smoking, pregnancy and obesity being important risk factors for
severe disease [3,4,5,6].
On 1
st August 2009, a 14 year-old girl without history of known
risk factors succumbed to p-H1N1-09 infection in Pune, western
India representing the first fatality from the country. As of 21
st
April 2010, India has reported 1483 deaths during the pandemic
(http://pib.nic.in/h1n1/h1n1.asp), Pune contributing to 173 cases
(http://www.maha-arogya.gov.in/march-april%202010.htm).
During the initial phase of the pandemic, designated wards in
the government hospitals admitted every mild case, treated with
Oseltamivir and discharged after recovery. A special intensive care
unit treated the critically ill patients. The present study was
undertaken during this very early phase of the pandemic. To
understand the basis of differential disease presentation/outcome,
we investigated 26 mild cases and 15 critically ill patients during 1
st
August – 19
th September 2009. This report provides comparative
data on viral load, cytokines, gene-profiling, Toll-like-receptor
(TLR) levels, antibody titres and antibody isotypes.
Materials and Methods
Patients and clinical specimens
Ethical clearance for the study was obtained from, ‘Institutional
Human Ethical Committee’ as part of the pandemic influenza
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participants involved in the study. For minors and critically ill
patients it was obtained from parent/guardian. Patients confirmed
to have p-H1N1-09 infection by a positive real time PCR test
(http://www.who.int/csr/resources/publications/swineflu/CDC
RealtimeRTPCRprotocol_SwineH1Ass-2009_20090428) were
studied. These included 15 patients admitted to Intensive Care
Unit and requiring mechanical ventilator support and 26
suffering from mild respiratory symptoms. All the mild cases
were ambulatory patients admitted to a designated hospital. In
the initial phases of the pandemic during which this study was
performed, patients suggestive of Influenza-like illness were
admitted to designated ward of a Corporation hospital. Throat
swabs were collected and sent to the National Institute of
Virology for diagnosis. Osletamivir treatment was initiated
immediately after the confirmation of diagnosis. These patients
were discharged after the completion of the treatment. On the
contrary, majority of the severe patients were admitted only after
the development of serious respiratory consequences. Same
protocol was followed for diagnosis and antiviral treatment.
A single blood sample was collected from mild cases, 1-3 days
after the development of respiratory symptoms. As controls, blood
samples from 20 apparently healthy individuals were collected.
Sequential blood/lung aspirate samples (standardized tracheal
aspirates) were collected from the critically ill patients. The first
sample was collected within 3 days for 13 patients; while one each
was collected on 4 and 8 (pregnant woman) days after the
appearance of symptoms (Table 1). Blood and lung aspirates were
transported to the lab within half an hour of collection. Lung
aspirates obtained from severe cases were immediately aliquoted
and frozen at 280uC. An aliquot was mixed in 1:3 proportions
with the RNAlater and stored at 280uC for gene analysis.
Hundred microlitre of the blood sample from every patient was
processed immediately for TLR staining as described below. In
parallel, blood samples were immediately processed for the
isolation of Peripheral Blood Mononuclear Cells (PBMCs) by
density gradient centrifugation using Ficoll-Hypaque (Sigma).
Plasma layer was removed and stored at 280uC in aliquots; cell
pellets were stored in 500 ml RNALater solution (Ambion) at
280uC.
ELISA for IgG-anti-p-H1N1 antibodies and isotyping
A highly sensitive and specific ELISA was carried out by coating
the wells with purified recombinant HA protein (expressed in
baculovirus system) of p-H1N1-09 virus, sera at 1:100 dilution and
anti-human-IgG-HRP conjugate as the detector antibody [7].
Isotyping was done as described earlier [8].
TLR staining and flow cytometry analysis
Anti-human antibodies for TLR 2, 3, 4 and 9 (eBioscience,
USA) and TLR 7 and TLR 8 (Imgenex, USA) were used for the
staining. For surface staining of TLR 2 and 4, 100 ml of whole
blood was lysed with BD FACS lysis solution (BD Biosciences,
USA), washed, fixed and processed for staining with anti-human
TLR 2 (FITC conjugated) and TLR 4 (PE conjugated) antibodies
respectively. For intracellular staining, 100 ml of the whole blood
was fully lysed with BD FACS lysing solution (Becton Dickinson),
washed twice with Perm-wash buffer (BD bioscience) and
processed for staining with the following anti-human antibodies:
PE- TLR 3, FITC- TLR 7, FITC- TLR8 and PE-TLR 9
respectively. Stained cells were resuspended in 500 ml1 %
paraformaldehyde, analysed on FACScalibur flow cytometer
(Becton Dickinson).On the basis of forward and side scatter plot
lymphocytes and monocytes were gated and data analysis was
done using BD FACSDivasoftware.TLR levels were expressed as
median fluorescence intensity (MFI).
Cytokine measurements
Concentrations in the plasma/lung aspirates were determined
for seventeen cytokines/chemokines (IL1a, IL1b, IL6, TNFa,
Table 1. Characteristics of the critically ill patients admitted to the Intensive care unit.
Identification Age/sex
Sickness duration
before admission
(days in hospital)
Lung radiological
findings (of 6 zone
involvement) Co-morbidities Outcome Lung aspirates
p-09-S1 28M 3 (7) ,3 Asthma Survived Yes
p-09-S2 19M 3 (4) ,3 None Survived Yes
p-09-S3 25F 8 (10) $3 Pregnancy, 16 wks Death Yes
p-09-S4 53M 1 (8) $3 RHD Death Yes
p-09-S5 40M 3 (10) $3 None Death Yes
p-09-S6 40M 3 (12) $3 DM/HT Death Yes
p-09-S7 32F 3 (4) ,3 None Death Yes
p-09-S8 35F 2 (2) $3 RHD Death Yes
p-09-S9 46M 4 (10) $3 HIV-1 +ve Death No
p-09-S10 35F 1 (1) $3 None Death No
p-09-S11 22F 2 (2) $3 None Death Yes
p-09-S12 14F 1 (1) $3 None Death Yes
p-09-S13 40F 2 (1) $3 RHD Death No
p-09-S14 13F 2 (1) $3 None Death No
p-09-S15 43F 1 (2) $3 Obesity Death No
s-09-S21** 36F 3 (39) $3 None survived Yes
**Suffering from seasonal influenza; RHD= Rheumatoid heart disease, DM= Diabetes mellitus, HT= Hypertension.
doi:10.1371/journal.pone.0013099.t001
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TRAIL, CXCL8, CCL3 and CCL4) on Bio-Plex Protein Array
System (Bio-Rad, Hercules, CA, USA) using Milliplex Map Kit
(Millipore) as per the manufacturer’s instructions.
Total RNA extraction and gene expression analysis
Frozen lung aspirates were thawed, centrifuged to pellet down
the cells and pellets were used to isolate RNA. Total RNA was
extracted from PBMCs and lung aspirate cells by using Ribopure
Kit (Ambion) as per the manufacturer’s instructions. RNA was
eluted in 100 ml elution buffer, quantitated using Nanodrop (ND-
1000) and processed for quality check in Agilent bioanalyzer
(Agilent, U.S.A). Equal quantities of RNA (500 ng) with $7 RIN
value were processed further for cDNA synthesis using High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
U.K.). All cDNAs were tested in real time PCR assay using
TaqMan primers and probe for 18S rRNA (Applied Biosystems,
U.K.) to ensure efficient cDNA synthesis. cDNAs were mixed with
equal volumes of TaqMan 2X PCR master mix from one-step
RT-PCR kit (Applied Biosystems) and 125 ng (RNA equivalent)
cDNAs were loaded per port of the TaqMan Low Density Array
card (TLDA) of the Human Immune panel (Applied Biosystems,
U.K.) and run on 7900HT Fast Real-Time PCR system (Applied
Biosystems, U.K.). Relative gene expression values were obtained
employing comparative Ct method using Applied Biosystems’
Relative Quantification (RQ) Manager Software v1.2. cDNAs
from six healthy individuals processed similarly were considered as
calibrators. 18s RNA was used as an endogenous control. Relative
quantitation values of each study group were used to calculate
mean RQ values. For cluster analysis, relative quantitation values
were log2 transformed and hierarchically clustered with analysis
software (Cluster 3.0) [9].
Viral RNA Titres
Viral RNA was extracted from 140 ml plasma/lung aspirates
using QIAamp Viral RNA Mini Kit (Qiagen, Germany) as per the
manufacturers’ instructions. For viral RNA quantitation, CDC
primers and probe were used. The target HA gene from an Indian
isolate was cloned to obtain in vitro transcripts, serial 10-fold
dilutions of the RNA were used to generate a reference curve. A
linear relationship was obtained from 10
10–10
2 starting copies/
reaction (r
2=0.99), the detection limit being 100 copies.
Statistical Analysis
Levels of cytokines and chemokines were analyzed after log
transformation and a value of 0.2 pg/ml was used in the case of
undetectable concentration of cytokine or chemokine in the tested
samples. The Mann-Whitney U or Fisher exact tests were used for
group comparisons of numerical and categorical data respectively.
For all analyses, a P value of less than 0.05 derived from a two
tailed test was considered significant. All statistical analyses were
performed with ‘SPSS11.0 for Windows’ software (SPSS Inc.).
Results
All the 26 mild cases (Male: Female ratio 12:14, age range 6–
51 yrs) had fever/history of fever in last 3 days. The other
symptoms included sore throat/cough (14/26), nasal discharge (6/
24), headache/bodyache (5/26), diarrhea (2/26) and breathless-
ness (4/26). Radiological examination was not indicated and
hence not performed. Nasal oxygen was not required.
Of the 15 critically ill patients, 2 survived (Table 1). The
male:female ratio was 6:9, the age range being 13–53 years.
Associated co-morbidities were present in 1/2 surviving and 7/13
fatal patients. Importantly, radiological findings showed that all
the fatal cases had $3/6 lung zonal involvement and required
ventilator assistance. Both the surviving patients initially needed
nasal oxygen but were put on ventilator subsequently. The
patients were either treated with Osletamivir alone (n=7) or in
combination with Zanamivir (n=8). From the endotracheal tubes
of 4 patients Acenotobacter was isolated. None of the 26 mild
cases had recognizable risk factors. S21, a 36 year female
suffering from severe seasonal influenza survived after 39 days of
hospitalization.
Viral load
Plasma samples from both patient categories were negative for
pH1N1-09 influenza virus RNA. Sequential lung aspirate samples
of 6 patients (2–5 samples) demonstrated gradual/continued lower
or no viral load. Of the single lung aspirate from 3 patients with
rapid death, two were negative for viral RNA while one exhibited
1.51610
5 copies/ml (Figure 1).
Antibody titres
Serum samples available from 4 critically ill patients exhibited
HI titres of 40–320. At admission, the geometric mean titres
(GMT) of anti-rpH1N1-09-HA-IgG antibodies (ELISA) were
significantly lower in the mild infections (800, 95% CI values
571–1120) than the critically ill patients (4996, 95% CI values
3970–6288) (p,0.0001). The last blood sample collected 4–11
days later from 11 critically ill patients showed .4 fold rise in
antibody titres. IgG1 was the exclusive isotype in both the
categories.
TLR levels
Figure 2a shows representative FACS plots of TLR analysis.
The expression of TLR3, TLR4, TLR7, TLR8 and TLR9 was
significantly higher in mild cases than controls (p=0.0081, 0.0000,
0.0065, 0.0000, 0.0000 respectively), TLR2 not being different
(p=0.22) (Figure 2b). Comparison of the disease categories
revealed significant decrease in TLR 2 (p=0.0009) and rise in
TLR3, TLR4, TLR7 levels (p=0.0078, 0.019, 0.0070 respective-
ly) in critically ill patients. Levels of TLR8 and TLR9 remained
unchanged (p=0.12, 0.93).
Cytokine levels
Comparison among healthy controls and disease categories
showed no difference in the levels of IFNc, IL12p70 and IL2RA
were significantly lower in mild cases and higher in critically ill
patients (Table 2). All other molecules showed significantly higher
levels in both patient categories. The overall pattern reflects
pandemic-H1N1-09 influenza infection. The disease severity
correlated with significant increase in IL1RA, IL2, IL6, CCL3,
CCL4 and IL10 levels in critically ill patients.
Gene-profiling (PBMCs)
Analysis of gene expression profiles revealed significant findings;
please see Table S1:
Comparison of controls with disease categories.
1. Down-regulation of IL15, NOS2A, CCR4 and up-regulation
of IL17, CYP7A1, SELE, IL5, RPL3L genes in both patient
categories indicative of response to p-H1N1-09 virus infection.
2. Only in critically ill patients, CCL3, CCL19, CCR7, IL1A,
1L1B, IFNG, CD34, CD80, BAX, COL4A5, EDN1,
TNFRSF18, PTPRC, SKI were down-regulated while HLA
DRB1, IL9 and IL6 were up-regulated.
Immune Response Influenza
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while IL-4 was up-regulated in critically ill patients and down-
regulated in mild cases.
Comparison among the patient categories. A large
number of genes were significantly down-regulated in critically
ill patients than in the mild cases (CCL2, CCR5, TNF, IL2, IL13,
CD3E, CD4, CD8A, CD28, CD40, CD40LG, CD86, CTLA4,
FASLG, HLA DRA, ICOS, ACE, BCL2, C3, CSF1, GNLY,
GZMB, IKBKB, LTA, PRF1, SMAD3, SMAD7, and TBX21).
Lung aspirate analysis
Tables 2 and S1 represent the status of cytokines and
chemokines at protein and gene levels respectively in the lung
aspirates/cells of lung aspirates of critically ill patients. In the
absence of similar samples from mild cases/healthy controls for
ethical reasons, no comparison was possible.
Comparison of plasma and lung aspirates of critically ill patients
identified higher levels of CXCL8 and IL12p70 in the lung
aspirates. No significant difference was noted for the other
molecules. None of the plasma markers of severity exhibited
higher levels in the lung aspirates.
Following patterns emerged from the gene profiling compari-
sons of PBMCs and lung cells of critically ill patients:
1. Genes showing down-regulation in both: CD40LG and
SMAD7. Both genes were significantly down-regulated in the
PBMCs of critically ill patients than mild cases.
2. Genes showing up-regulation in both: CCL2, IL6, IL10, IL17,
HLA DRB1, CYP7A1, SELE. Except CCL2, all other genes
exhibited insignificant difference when PBMCs from mild and
critically ill patients were compared.
3. Genes showing up-regulation in lung and down-regulation in
PBMCs: CCL3, CCL19, IL1A, IL1B, TNF, CD80, ACE, C3,
COL4A5, CSF2, EDN1, NOS2A.
4. Genes showing basal levels in PBMCs and up/down-regulation
in the lung: Except for down-regulation of IL12A, all other
genes were up-regulated in lung. These included: CXCL8,
CXCL10, CXCL11, ICAM1, CSF1, HMOX1, STAT3,
CD68, CSF3, FN1, NFKB2, TFRC, VEGF and IL12B.
5. Genes showing basal levels in the lung and up/down regulation
in PBMCs: Except for the up-regulation of IL5 and IL9, all
other genes were down-regulated in PBMCs (IFNG, CCR4,
CCR7, CD3E, CD4, CD8A, CD28, CD34, CTLA4, BAX,
Figure 1. Virus titres in the lung aspirates of critically ill patients. RNA log10 copies/ml were determined by HA gene based real-time
PCR assay. Y-axis represents different patients and samples obtained days post admission of the sequential samples of respective patients (S1-1,
S1-2, …and S12-1).
doi:10.1371/journal.pone.0013099.g001
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and TNFRSF18).
6. Genes unchanged in lungs and PBMCs: CD40, CD86,
FASLG, GZMB, LTA, CCR5 and ICOS.
Expression patterns of genes were also analyzed by hierarchical
clustering. Results are graphically represented by assigning a
specific color to each cell on the basis of the expression levels.
Genes showing no changes in expression levels (as compared to
controls) are shown as black. Upregulated genes are shown in red
with increasing intensities in proportion to the expression levels
and in different intensities of green indicating levels of downreg-
ulation. Figure 3a shows cluster image of samples from mild and
critically ill cases taken on admission. Seasonal flu sample (S21)
showed a distinct gene expression pattern and formed a separate
cluster (cluster 6) from all other samples. Three lung samples from
critically ill patients also formed a separate cluster as most of the
proinflammatory genes were upregulated (cluster 2). Remaining
samples formed mixed clusters (cluster 4 and 5) which included
both mild and critically ill patients. Overall, no distinct clustering
pattern for the patients was observed for the severe and mild cases.
With respect to gene clustering, clusters A and B contained genes
associated with inflammation.
Comparisons of genes of lungs and PBMCs of the same 3
patients or all the critically ill patients as a group yielded similar
results.
Comparison of lung cytokines and chemokines at protein and
gene levels showed comparable elevated levels of IL12B, CXCL8,
IL1B, CCL3, IL1A and IL6 while IL17, TNF and IL10 were
elevated only at the gene level. IFNG was at basal level both at
gene and protein levels.
Sequential analysis
Variable numbers of sequential blood samples were available
from critically ill patients. Comparisons of TLRs did not show any
distinguishable pattern (data not shown). For evaluating gene
expressions, a separate cluster analysis was carried out for the
sequential PBMC samples of critically ill patients (Figure 3b).
Samples formed two distinct clusters. Samples from S1, S2, S3 and
S4 formed a single cluster (cluster 1) showing significant
Figure 2. TLR levels in the blood lymphocytes and monocytes. TLR levels of peripheral blood from the patients and healthy controls were
determined separately by either surface staining or intracellular staining of the cells using TLR specific antibodies followed by FACS analysis. Scatter
dot plots and histograms: A representative sample each from different categories, a) healthy individual, b) mild case, c) critically ill case,d ) TLR
levels: Expressed as median fluorescence intensities (MFI) for different categories of patients.
doi:10.1371/journal.pone.0013099.g002
Table 2. Levels of chemokines and cytokines in the peripheral blood.
Values represent Median log10pg/ml (range)
Critically ill patients p Value
a p Value
b Mild cases p Value
c Healthy Controls
Lung
Aspirates
Pro-Inflammatory Cytokines
IL1a 1.64 (20.70–3.26) 0.2061 0.0032 20.70 (20.70–3.26) 0.0312 20.70 (20.70–3.28) 2.81 (0.48–3.21)
IL1b 0.48 (20.70–1.05) 0.2639 0.0053 0.32 (20.70–1.80) 0.0006 20.70 (20.70–0.72) 2.05 (0.48–2.68)
IL6 2.14 (0.40–3.11) 0.0022 0.0000 0.32 (20.70–3.11) 0.0001 Undetected 2.59 (0.48–3.29)
TNFa 0.48 (0.48–1.06) 0.3697 0.0000 0.70 (20.70–4.41) 0.0000 Undetected 0.48 (0.48–0.48)
IL17 0.48 (20.70–2.14) 0.2608 0.0002 0.18 (0.08–1.62) 0.0000 20.70 (20.70–0.61) 0.48 (0.48–1.07)
Anti-Inflammatory
Cytokines
IL1RA 1.23 (20.70–3.20) 0.0220 0.0000 0.82 (20.70–1.84) 0.0001 Undetected 2.55 (0.48–3.01)
IL2RA 0.91 (20.01–1.18) 0.4438 0.0000 20.10 (20.10–2.92) 0.0000 Undetected 2.27 (0.48–2.58)
IL10 1.71 (20.70–2.59) 0.0135 0.0000 20.70 20.70–2.38) 0.0011 Undetected 0.48 (0.48–2.59)
Th-1 Cytokines
IL2 0.48 (0.01–1.31) 0.0002 0.0000 20.70 (20.70–0.53) 0.0032 Undetected 0.48 (0.48–2.52)
IL12p70 0.26 (20.70–0.32) 0.6705 1.0000 0.20 (0.05–0.32) 0.4417 0.20 (0.05–0.32) 0.48 (0.48–2.74)
IL12p40 0.48 (20.70–2.76) 0.2655 0.0000 0.32 (0.08–2.18) 0.0000 Undetected 2.40 (0.48–2.74)
Chemokines
CXCL5 3.30 (20.70–3.71) 0.1580 0.0001 20.70 (20.70–3.55) 0.0039 Undetected 2.92 (1.13–3.78)
CXCL8 1.37 (20.70–3.63) 0.5150 0.0000 1.10 (0.20–3.65) 0.0000 Undetected 4 (0.48–4.04)
MIF 3.33 (3.13–4.24) 0.4368 0.0072 3.45 (3.13–4.05) 0.0009 3.08 (2.11–3.69) 4.18 (1.08–5.42)
CCL3 1.66 (20.70–2.25) 0.0224 0.0000 20.70 (20.70–2.28) 0.0032 Undetected 1.54 (0.48–2.80)
CCL4 1.89 (20.70–2.84) 0.0495 0.0000 1.57 (20.70–2.0) 0.0001 Undetected 2.59 (0.08–3.43)
TRAIL 0.15 (20.70–3.09) 0.2866 0.0032 0.15 (20.70–3.09) 0.0012 20.70 (20.70–3.51) 1.89 (20.30–
2.76)
a* p value between critically ill patients and mild cases.
b* p values between critically ill patients and healthy controls.
c* p values between mild cases and healthy controls.
doi:10.1371/journal.pone.0013099.t002
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contained all sequential samples from the seasonal flu case (S21)
and one pH1N1 case (S7). Though most of the gene expression
levels were similar to survived case, S7 did not survive. Genes
formed four clusters, A, B, C and D. Cluster C contained majority
of the analyzed genes (73/87) and all were downregulated in the
cluster 1.
The dynamics of cytokines/chemokines at protein levels (6
patients) are shown in Figure 4. Data for the single critical patient
suffering from seasonal influenza (S21) is also presented.
Comparison of plasma cytokines and chemokines did not show
any distinct pattern in the sequential samples of the fatal or
survived cases. Patient S6 did exhibit different pattern when
compared to others.
Discussion
This first comprehensive study addresses important issues of
the identification of markers for severity of p-H1N1-09 infection
and dynamics of immune responses in severe disease by
evaluating several parameters. The investigations were initiated
during the early phase of the pandemic when isolation of all the
Figure 3. Gene expression analysis. Gene expression profiles of total PBMCs from blood samples of mild and critically ill cases and lung aspirate
cells from critically ill cases were determined using TaqMan Low Density immune panel arrays. PBMCs from six healthy individuals were taken as
controls, which were treated as replicate arrays to calculate the mean baseline expression level for each gene. The fold changes in the gene
expression levels were calculated in relation with the controls. Values for eighty-seven genes were hierarchically clustered on log2 transformation.
The corresponding gene of each cluster is listed by a gene symbol on the right-hand side of the images. a) Cluster image of gene expression
analysis of PBMCs from mild and critically ill cases and lung aspirate cells from critically ill cases: PBMC samples from mild cases are
denoted as M (M1, M2, M13). First sample taken after admission from each critically ill case was taken for the comparison and are denoted as S1-1, S2-
1, S21-1. Single samples from critically ill patients are denoted as S8, S12 etc. Lung aspirate samples are denoted as L. b) Cluster image of gene
expression analysis of sequential blood samples from critically ill cases: Total PBMCs from the sequential blood samples of severe cases
obtained on different post admission days are denoted as S1-1, S1-2, …S21-8).
doi:10.1371/journal.pone.0013099.g003
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in the sequential blood samples obtained on different post infection days from critically ill patients. M represents mean values of the corresponding
molecule levels in the plasma of 21 mild cases. a) Pro-inflammatory cytokines-1. b) Pro-inflammatory cytokines-2. c) Chemokines-1. d)
Chemokines-2. e) Anti-inflammatory cytokines. f) Th1 cytokines.
doi:10.1371/journal.pone.0013099.g004
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Therefore, we could collect samples before the initiation of the
antiviral therapy and the data truly represents acute phase of mild
disease. On the other hand, critically ill patients were given
Oseltamivir immediately after the confirmation of the infection
and the samples were collected subsequently. As underlying
medical conditions were present in one of the 2 survivors and 7/
13 critically ill patients, association of co-morbidities alone does
not seem to be responsible for complications or aberrant immune
response.
The absence of viremia in both patient categories and
relatively low viral load in the lung aspirates of the critically ill
patients suggest that enhanced replication of the virus may not
be an important contributor to the pathogenesis (Figure 1).
The viral load in lung aspirates was independent of fatality. In
contrast, among the Spanish patients [10], 93% and 57% of
the mild and critical cases respectively were positive for serum
viral RNA, with no significant difference in the viral load. Both
studies used CDC primers for real time PCR (http://www.
who.int/csr/resources/publications/swineflu/CDCRealtimeR
TPCRprotocol_SwineH1Ass-2009_20090428) and the critical
cases were bled when already on Oseltamivir treatment,
negating sensitivity of the PCR, effect of antiviral therapy or
delay in collection of samples to be responsible for different
results. The absence of uniform mutations in the fatal cases-
derived Indian p-H1N1-09 isolates suggests limited/no role of
mutant virus in the pathogenesis [11]. Viremia was associated
with the outcome of H5N1 infection, 9/11 fatal and 0/5 non-
fatal cases being viremic [12].
Serum HI-antibody positivity was noted in 1/15mild, 2/10
critically ill Spanish patients and 4/4 critically ill patients from
India. ELISA could detect antibodies in every patient. The
absence of viremia among the Indian patients may be due to an
early antibody response.
The presence of IgG-anti-p-H1N1-09 antibodies in all the
severe Indian patients (HI antibodies in all the 4 screened) does
indicate switch from the innate to adaptive immunity. Poor
outcome despite the switch may probably be attributed to the
timing of the shift or role of antibodies in disease severity.
Significantly higher titres of IgG-anti-p-H1N1-09 antibodies in the
critically ill patients supports the role in pathogenesis. This
observation is in sharp contrast with that for the SARS patients
examined from Canada [13] documenting significantly lower anti-
SARS CoV spike antibody titres in the critically ill patients.
Though the presence of neutralizing antibodies protect against
Influenza virus infection, clearance of the infection is mediated by
cellular immunity. The exclusive presence of IgG1 antibodies in
both patient categories document Th2 bias with significant
enhancement with severity. This observation correlates with the
elevated levels of TLR3, 4, and 7, Th2 cytokines (IL6 and IL10) at
protein level and IL4, IL5, IL6, IL10 at gene level.
We identified higher plasma levels of IL1RA, IL2, IL6, CCL3,
CCL4 and IL10 as markers of severity. Of these, IL6 is a known
marker of influenza disease severity with probable involvement in
tissue damage [12,14]. CCL3 and CCL4 are important mediators
of virus induced inflammation. IL10 is recognized as a regulatory
(anti-inflammatory) cytokine and can act on multiple cell types to
regulate immune and inflammatory responses [15]. IL6 is known
to be responsible for regulating plasma levels of IL1RA and IL10
[16]. Among Spanish patients, serum IL15, IL12p70 and IL6 were
recognized as the hallmark of severity [10]. Significant increases in
TLR levels without corresponding rise in cytokines suggest
aberrant immune response in critically ill patients. The possibility
of viral proteins diminishing cytokine production cannot be ruled
out. Similar to in-vitro studies [17,18], cytokine storm associated
with pathogenesis of H5N1 infection [12] was not the feature of p-
H1N1-09 infection. The observations of no increase in the levels of
plasma IFNG in both patient categories when compared to
controls as well as basal gene expression in the lungs of critically ill
patients point out lack of co-ordination in the modulation of innate
and adaptive immune responses.
At PBMC gene level, down-regulation of a large number of
genes was associated with disease severity (Table S1, Figure 3b).
This profile is indicative of massive infiltration of monocyte-
recruited neutrophils, DCs/macrophages to the target organ for
mounting immune response/tissue repair and/or viral protein-
induced shut down of the cellular genes, as these cells are known to
efficiently replicate the virus [19,20]. Additional studies are
required to examine if the virus specifically down regulates host
antiviral genes or dictates generalized shut down of host mRNA
synthesis [19,21], especially in relation to the disease severity.
Paradoxically, constant inflammatory signals provided by the
significant increase in several chemokines (CCL2, CCL3, CCL19,
CXCL8, CXCL10, CXCL11) and pro-inflammatory cytokines
(IL6, IL17, IL1A, IL1B, TNF) in the lung cells may have resulted
in massive infiltration of leucocytes and excessive tissue damage.
This is to our knowledge the first report on p-H1N1-09-induced
gene expression in human lung cells.
As against differential cytokine levels and viral load observed in
a male and pregnant female fatal H5N1 case [21], except for
higher down-regulation of IL1B/IL2, the pregnant woman (S3) in
our series was similar to others. It was intriguing to note that
despite attempts of mounting immune response similar to mild-
recovered patients, the patient S7 did succumb to the disease. It is
important to recognize that the current study examines virus-host
interactions throughout the course of severe disease, limitation of
the study being absence of similar data from mild cases.
We could investigate a critical case suffering from seasonal
influenza (S21). As against similar patterns recorded for pandemic
influenza cases, distinct differences were recorded for this case
(Figure 3a, 3b).
In the ferret model with 27% mortality based on the .20%
weight loss following infection with A/California/07/2009
pandemic influenza virus [22], sequential lung sampling docu-
mented decreased gene expression of CCL2, CXCL10, TNFA
and IL1B on day 7 when animals show highest weight loss.
Comparison of the human data presented in our study (Table S1)
shows that in the lungs of the critically ill patients all these and
several other chemokines/inflammatory cytokines are over-
expressed. Thus, the gene expression profiles at the time of
overwhelming symptoms in the lungs of the infected ferrets
(decreased expression) do not match the data on severe human
cases from the present series (elevated expressions).
While finalizing the manuscript, we came across two studies
from Hong Kong [23,24]. The mild patients (n=22) were non
viremic while 13% of the 23 fatal cases were viremic. Data from
Spain, Hong Kong and India suggests the role of host genetics in
immune response to the pandemic-causing virus.
In conclusion, our data confirms earlier findings of dysregulated
host response in severe infections with H5N1 [12] and 1918
influenza viruses [25,26,27]. However, the mechanisms leading to
similar end results seem to vary with the type of viral infection. In-
depth studies to understand the role of virus/viral proteins in
modulating host response need to be undertaken on priority.
Identification of specific pathways might provide clues to include
immunomodulators for the treatment of severe cases, albeit in
conjunction with potent antivirals.
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